Compare Dow Inc (DOW) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Medpace Holdings Inc — how do they compare? Dow Inc trades at $28.46 (market cap $20.65B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays a 4.9% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Medpace Holdings Inc for 14 Days on average.
| DOW | MEDP | |
|---|---|---|
Market Cap | $20.65B | $16.82B |
Volume | 14,126,943 | 223,093 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $630.19 |
52-Week Low | $20.65 | $393.42 |
Typical Hold Time | 82 Days | 14 Days |
Enterprise Value | $36.34B | $16.44B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.42, up 2.34% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported negative net income of -$2.62B in 2025, though it has beaten EPS estimates in recent quarters. Revenue declined to $39.97B in 2025 from $56.9B in 2022, while cash flow from operations dropped significantly. Analyst consensus is a 'Hold' with a $34.22 price target, indicating potential upside from current levels.
The outlook for DOW is cautious due to profitability challenges and declining revenue, offset by positive earnings surprises and a dividend payment. Key risks include margin pressures and high debt levels, while opportunities lie in cost management and market recovery. Investors should weigh the stock's valuation against its financial health and sector headwinds.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
